Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Annual Information Update

21 May 2012 07:00

RNS Number : 7297D
PuriCore Plc
21 May 2012
 



 

PuriCore plc Annual Information Update 

PuriCore (LSE: PURI), the water-based clean technology company, today sets out below a list of the information that has been published or made available to the public over the previous 12 months, up to and including 20 May 2012.

 

The Company announces that, in accordance with Rule 5.2 of the Prospectus Rules, the following information was published or made available to the public during the 12-month period between 18 May 2011 and 20 May 2012. In accordance with Prospectus Rule 5.2.7, it is acknowledged that whilst the information referred to above was up to date at the time of publication, such disclosures may, at any time, become out of date due to changing circumstances. For the purposes of this update, the information is referred to rather than provided in full. Full copies of each item can be found in the locations specified below.

 

1. Announcements made via the Regulatory Information Service

 

Copies of the announcements made via the Regulatory Information Service may be obtained from the Company's website at www.puricore.com or from the Regulatory News Service provided by the London Stock Exchange at www.londonstockexchange.com.

 

Date Headline

30/04/2012

26/04/2012

PuriCore plc - Director Dealing and Share Option Grant

PuriCore plc -Final Results

26/04/2012

PuriCore plc -Interim Management Statement

25/04/2012

PuriCore plc -Notice of Results

29/03/2012

PuriCore plc -Appointment of New Chairman and Board Changes

13/02/2012

PuriCore plc -Notification of Director's Details

03/02/2012

PuriCore plc -Directors Dealings and Share Option Grants

02/02/2012

PuriCore plc -Blocklisting Interim Review

01/02/2012

PuriCore plc -BBSRC Industrial Partner Award

01/02/2012

PuriCore plc -Directorate Change

01/02/2012

PuriCore plc -Pre-Close Trading Update

17/01/2012

PuriCore plc -PuriCore Aqualox EPA Confirmation

03/01/2012

PuriCore plc -Raises $3.5 Million Debt Facility

30/12/2011

PuriCore plc -Total Voting Rights

19/12/2011

PuriCore plc -PuriCore Receives Two Major Contracts-Replacement

19/12/2011

PuriCore plc -PuriCore Receives Two Major Contracts

14/12/2011

PuriCore plc -Agriculture System Confirmed for Use by EPA

13/12/2011

PuriCore plc -Convertible Loan Notes Extension

18/11/2011

PuriCore plc -Interim Management Statement

21/10/2011

PuriCore plc -Convertible Loan Notes Update

10/10/2011

PuriCore plc -Holding(s) in Company

22/09/2011

PuriCore plc -Board and Organisational Changes

16/09/2011

PuriCore plc -New $1.9 Million Debt Facility Agreed

05/09/2011

PuriCore plc -Second Price Monitoring Extension

05/09/2011

PuriCore plc -Price Monitoring Extension

23/08/2011

PuriCore plc - Half Yearly Report

21/07/2011

PuriCore plc - Re Settlement with Misonix

15/06/2011

PuriCore plc - Result of AGM

18/05/2011

PuriCore plc - Annual Information Update

 

2. Documents filed at Companies House

 

Copies of these documents can be obtained from Companies House at Crown Way, Maindy, Cardiff CF14 3UZ or from the Companies House website at www.companieshouse.co.uk.

 

Date

Document

Description

18/05/2012

AR01

Annual Return

17/04/2012

CH01

Director's Change of Particulars/Mr Gregory Todd Bosch

17/04/2012

CH01

Director's Change of Particulars/Mr Joseph William Birkett

17/04/2012

CH01

Director's Change of Particulars/Mr Michael Sapountzoglou

17/04/2012

CH01

Director's Change of Particulars/Mr Matthew Charles Perrins Hammond

13/04/2012

AP01

Director Appointed James Walsh

10/04/2012

CH01

Director's Change of Particulars/Mr Michael Richard Dwyer Ashton

04/04/2012

AP01

Director Appointed Michael Richard Dwyer Ashton

29/03/2012

TM01

Appointment Terminated, Director Christopher Wightman

25/01/2012

AD01

Registered Office Changed from 25 Farringdon Street, 6th Floor, London, EC4A 4AB United Kingdom

05/12/2011

AD02

Sail Address Changed from Equiniti Holm Oak Hold Oak Business Centre Woods Way, Goring by Sea, Worthing, West Sussex, BN12 4FE

07/10/2011

TM01

Appointment Terminated, Director Darren Weiss

07/10/2011

TM02

Appointment Terminated, Secretary Darren Weiss

07/10/2011

AP03

Secretary Appointed Marella Thorell

23/06/20

AP03

Secretary Appointed Mr Darren Douglas Weiss

23/06/2011

TM02

Appointment Terminated, Secretary Andrea Holtzman Drucker

20/06/2011

RES10

Authorised Allotment of Shares and Debentures

20/06/2011

AA

Group of Companies' Accounts Made Up to 31/12/10

 

3. Documents sent to shareholders or submitted to the UKLA

 

Copies of these documents are available for viewing on the website of the National Storage Mechanism at www.hemscott.com/nsm.do or on the Company's website at www.puricore.com.

 

Date

Description

26/04/2012

2011 Annual Report and Accounts, Notice of Annual General Meeting and Form of Proxy

 

Registered Office

PuriCore plc

Wolseley Court

Staffordshire Technology Park

Stafford

ST18 0GA

UK 

 

Marella Thorell

Company Secretary

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AIUFMGZKKMZGZZG
Date   Source Headline
9th Oct 20185:02 pmRNSForm 8.3 - Realm Therapeutics PLC
9th Oct 201810:13 amRNSForm 8.3 - Realm Therapeutics plc
5th Oct 20186:08 pmBUSForm 8.3 - Realm Therapeutics PLC
5th Oct 20182:00 pmRNSFORM 8.3 - Realm Therapeutics Plc
4th Oct 20188:57 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics plc
2nd Oct 201810:43 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics PLC
1st Oct 20187:00 amRNSProvides Update on Timing of Formal Sale Process
24th Sep 20189:59 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Sep 201811:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20183:16 pmRNSHolding(s) in Company
20th Sep 201811:53 amRNSForm 8.3 - REALM THERAPEUTICS PLC
20th Sep 201811:18 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Sep 20184:31 pmRNSForm 8 (OPD) - Realm Therapeutics plc
19th Sep 201811:11 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
18th Sep 201811:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
17th Sep 20187:00 amRNSCorporate Update and Hiring of Advisor
20th Aug 201811:00 amRNSPrice Monitoring Extension
20th Aug 20187:00 amRNSBlock listing Interim Review
15th Aug 20184:35 pmRNSPrice Monitoring Extension
14th Aug 20187:10 amRNSHalf-year Report
8th Aug 20187:00 amRNSPresents at Wedbush PacGrow Healthcare Conference
7th Aug 20187:00 amRNSNotice of Results
16th Jul 20185:33 pmRNSHolding(s) in Company
10th Jul 20187:00 amRNSPre-Clinical Study in Atopic Dermatitis
4th Jul 20187:00 amRNSInstructions for Exchanging Ordinary Shares
4th Jul 20187:00 amRNSSEC registration effective NASDAQ listing approved
14th Jun 201810:54 amRNSResult of AGM
31st May 20187:00 amRNSRealm to Present at June Investor Conferences
24th May 20187:00 amRNSEnrollment complete for Phase 2 study of PR022
23rd May 20187:00 amRNSFiling with US SEC to Facilitate Nasdaq Listing
21st May 20187:00 amRNSData Presentation at IID 2018
2nd May 201812:39 pmRNSAnnual Financial Report Available
2nd May 20187:00 amRNSFinal Results
2nd May 20187:00 amRNSRealm Files Registration for Nasdaq Listing of ADS
26th Apr 20182:32 pmRNSNotice of Results
12th Mar 20184:40 pmRNSSecond Price Monitoring Extn
12th Mar 20184:35 pmRNSPrice Monitoring Extension
12th Mar 20187:00 amRNSClinical Update including PR013 Phase II results
8th Mar 20187:00 amRNSPresenting at Cowen Healthcare Conference
27th Feb 20187:00 amRNSPatent portfolio strengthened with USPTO allowance
20th Feb 201812:00 pmRNSPresentation at RBC Healthcare Conference
16th Feb 20187:00 amRNSBlock listing Interim Review
15th Feb 20187:00 amRNSClinical and Business Update
2nd Jan 20187:00 amRNSPresents at 5th Annual Dermatology Summit
15th Dec 20177:00 amRNSDirector/PDMR Shareholding
12th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR013
5th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.